Recherche

Eto Bruno., Basilua, Joe Miantezila et Outman, Ahlam et Ndjip, Rosette Christelle et Alqahtani, Ali S et Bourhim, Mohamed et Ibet, Brahim et Ramadam, Issa et Torina, Claire et Pagui Panatere, Kady Tchalkoutou, Nour Mahamat, Janine Cordier, Bernard Gressier, Jehan-François Desjeux

Abstract:

Background/Objectives: Boscia senegalensis (BS) Pers.) Lam. Ex Poir (Capparaceae), is an important local famine food plant in Africa and widely exploited by healers for its seeds in Sahelian region to reduce hyperglycaemia. Purpose: We studied the efficacy of commercial dosage form of BS namely Boscisucrophage (BSP) on type 2 diabetes (T2DM) patients with Oral antihyperglycemic drugs resistant. Study Design: Clinical benefits of BSP, were evaluated in multicentre cohort observational study on naïve patients (43) or diabetic patients resistant of oral antidiabetic drugs (289). All patients received capsules of the fixed dose containing 350 mg of BSP twice daily for 12 weeks and overactive control on vein blood sugar, glycosylated haemoglobin (HbA1c), urine glucose excretion (UGE), aspartate aminotransferase, alanine aminotransferase, creatinine, and clinical examination of functional symptoms. Results: In clinical study, BSP induced the reduction of glycaemia, HbA1c, and increase UGE, with removal of side effects functional symptoms of T2DM. Conclusions: In clinical studies, our findings lend support to use of BSP to reduce glycaemia, and HbA1c in T2DM patients with Oral antihyperglycemic drugs resistant without over adverse effects. BSP supressed clinical examination of functional symptoms.

Keywords: glycosylated haemoglobin; Oral antihyperglycemic drugs resistant; diabetes type 2; Boscisucrophage; gliflozin; dual SGLT1 and SGLT2 inhibition

Preprints.org (www.preprints.org) August 2024 doi:10.20944/preprints202408.1121.v1